The Lancet Regional Health - Europe · Nov 14, 2026
Clone-censor weighting and dementia risk after statin initiation in diabetes: when the analyzed population is no longer the observed population
By Ahmed A, Coats AJS, Böhm M et al.
We read with interest the report by Ternhamar and colleagues about lower dementia risk with earlier statin initiation after diagnosis of type 2 diabetes in statin-naïve individuals.1 The authors should be commended for addressing one of the fundamental issues of observational studies, the prevalent-user bias, with the use of a new-user design. We highlight a less apparent issue for clinicians: the transition from real patients to cloned synthetic patients.